Roundtable Discussion: Late-Stage Clinical to Post-Approval Planning
Time: 11:15 am
day: Day 2 Track B AM
- How will drug scheduling impact manufacturing and what roadblocks can be mitigated?
- What safety profiles must be demonstrated and what are the biggest concerns
- What do the insurers anticipate will be the pattern of renumeration?